Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Ginwa Enterprise (Group) Inc. specializes in the development and manufacturing of specialty and generic pharmaceuticals, primarily serving the Chinese market. The company has a competitive edge through its high gross margins of 77%, but is currently facing significant revenue declines and profitability challenges.
Ginwa generates revenue through the sale of generic and specialty drugs, leveraging its strong R&D capabilities to develop cost-effective alternatives to branded medications. The company's pricing power is supported by its established relationships with hospitals and healthcare providers in China.
Changes in regulatory approvals for new drugs
Market share shifts in the Chinese pharmaceutical sector
Pricing pressures from competitors
Fluctuations in raw material costs
Regulatory changes affecting drug approvals and pricing
Technological disruption in drug manufacturing processes
Intense competition from both domestic and international generic drug manufacturers
Potential for new entrants in the specialty drug market
Low return on equity (1.2%) raises concerns about capital efficiency
Negative free cash flow (-$0.1B) could limit future investments
moderate - As a healthcare company, Ginwa's performance is somewhat insulated from economic downturns, but significant shifts in consumer spending can impact demand for non-essential pharmaceuticals.
Interest rates have minimal direct impact on Ginwa, but rising rates could affect overall economic conditions and consumer spending, indirectly influencing pharmaceutical sales.
minimal - The company's low debt levels (Debt/Equity of 0.02) indicate minimal reliance on credit markets.
value - Investors may be attracted to the low valuation metrics, but current operational challenges could deter growth-focused investors.
high - The stock has shown significant volatility with a 3-month return of -44.1%, indicating potential for rapid price movements.
